Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles

Soutschek, 2004, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nature, 432, 173, 10.1038/nature03121 Wolfrum, 2007, Mechanisms and optimization of in vivo delivery of lipophilic siRNAs, Nat Biotechnol, 25, 1149, 10.1038/nbt1339 Navab, 2011, HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms, Nat Rev Cardiol, 8, 222, 10.1038/nrcardio.2010.222 Rader, 2009, The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis, J Lipid Res, 50, S189, 10.1194/jlr.R800088-JLR200 Stein, 1999, Atheroprotective mechanisms of HDL, Atherosclerosis, 144, 285, 10.1016/S0021-9150(99)00065-9 Vaisar, 2007, Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL, J Clin Invest, 117, 746, 10.1172/JCI26206 Assmann, 2003, Atheroprotective effects of high-density lipoproteins, Annu Rev Med, 54, 321, 10.1146/annurev.med.54.101601.152409 Weisgraber, 1994, Apolipoprotein E: structure-function relationships, Adv Protein Chem, 45, 249, 10.1016/S0065-3233(08)60642-7 Mahley, 1999, Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond, Curr Opin Lipidol, 10, 207, 10.1097/00041433-199906000-00003 Jonas, 1986, Reconstitution of high density lipoproteins, Methods Enzymol, 128, 553, 10.1016/0076-6879(86)28092-1 Atkinson, 1986, Recombinant lipoproteins: implications for structure and assembly of native lipoproteins, Annu Rev Biophys Biophys Chem, 15, 403, 10.1146/annurev.bb.15.060186.002155 Innerarity, 1979, Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts, J Biol Chem, 254, 4186, 10.1016/S0021-9258(18)50713-4 Jonas, 1993, The number of amphipathic α-helical segments of apolipoproteins A-1, E, and A-IV determines the size and functional properties of their reconstituted lipoprotein particles, J Biol Chem, 268, 1596, 10.1016/S0021-9258(18)53895-3 Tardif, 2007, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial, JAMA, 297, 1675, 10.1001/jama.297.15.jpc70004 Newton, 2002, HDL therapy for the acute treatment of atherosclerosis, Atheroscler Suppl, 3, 31, 10.1016/S1567-5688(02)00044-2 Nicholls, 2006, Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-1 Milano, J Am Coll Cardiol, 47, 992, 10.1016/j.jacc.2005.11.040 Rensen, 2001, Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting, Adv Drug Deliv Rev, 47, 251, 10.1016/S0169-409X(01)00109-0 McConathy, 2008, Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel, Anticancer Drugs, 19, 183, 10.1097/CAD.0b013e3282f1da86 Denisov, 2007, Cooperativity in cytochrome P450 3A4, J Biol Chem, 282, 7066, 10.1074/jbc.M609589200 Bayburt, 2006, Assembly of single bacteriorhodopsin trimers in bilayer nanodiscs, Arch Biochem Biophys, 450, 215, 10.1016/j.abb.2006.03.013 Segrest, 1999, A detailed molecular belt model for apolipoprotein A-1 in discoidal high density lipoprotein, J Biol Chem, 274, 31755, 10.1074/jbc.274.45.31755 Martin, 2006, Apolipoprotein A-1 assumes a “looped belt ” confirmation on reconstituted high density lipoprotein, J Biol Chem, 281, 20418, 10.1074/jbc.M602077200 Shih, 2007, Disassembly of nanodiscs with cholate, Nano Lett, 7, 1692, 10.1021/nl0706906 Zimmermann, 2006, RNAi-mediated gene silencing in non-human primates, Nature, 441, 111, 10.1038/nature04688 Greeve, 1993, Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins, J Lipid Res, 34, 1367, 10.1016/S0022-2275(20)36966-2 Grass, 1995, Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans, J Lipid Res, 36, 1082, 10.1016/S0022-2275(20)39866-7 Wu, 2007, The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction, Nat Struct Mol Biol, 14, 861, 10.1038/nsmb1284 Morrissey, 2005, Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs, Nat Biotechnol, 23, 1002, 10.1038/nbt1122 Davis, 2009, The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic, Mol Pharm, 6, 659, 10.1021/mp900015y Akinc, 2008, A combinatorial library of lipid-like materials for delivery of RNAi therapeutics, Nat Biotechnol, 26, 561, 10.1038/nbt1402 Muratovska, 2004, Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells, FEBS Lett, 558, 63, 10.1016/S0014-5793(03)01505-9 Dassie, 2009, Systemic administration of optimized adpamer-siRNA chimeras promotes regression of PSMA-expressing tumors, Nat Biotechnol, 27, 839, 10.1038/nbt.1560 Zhou, 2010, Aptamer-targeted cell-specific RNA interference, Silence, 1, 4, 10.1186/1758-907X-1-4 Lerch, 1996, Production and characterization of a reconstituted high density lipoprotein for therapeutic applications, Vox Sang, 71, 155, 10.1046/j.1423-0410.1996.7130155.x Raal, 2010, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomized, double-blind, placebo-controlled trial, Lancet, 375, 998, 10.1016/S0140-6736(10)60284-X Visser, 2010, Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia, J Lip Res, 51, 1057, 10.1194/jlr.M002915 Frank-Kamenetsky, 2008, Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc Natl Acad Sci USA, 105, 11915, 10.1073/pnas.0805434105 Ding, 2008, Ab initio folding of proteins with all-atom discrete molecular dynamics, Structure, 16, 1010, 10.1016/j.str.2008.03.013 Ding, 2010, Rapid flexible docking using a stochastic rotamer library of ligands, J Chem Inf Model, 50, 1623, 10.1021/ci100218t